March 24 (Reuters) - Revive Therapeutics Ltd RVV.CD : * REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19 * REVIVE THERAPEUTICS LTD -...
Feb 26 (Reuters) - Revive Therapeutics Ltd RVV.CD : * REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19 WITH PLANNED COMPLETION AND...
Dec 23 (Reuters) - Revive Therapeutics Ltd RVV.CD : * REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19 WITH PLANS ON EMERGENCY USE...
TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused...
TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused...
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused...
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.10 | 3.10 | 2.94 | +0.150 | +5.08% | 19.66K | Toronto | |||
| 30.99 | 31.00 | 30.99 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 1.13 | 1.24 | 1.13 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 24.38 | 25.06 | 24.25 | -0.55 | -2.21% | 306.17K | Toronto | |||
| 78.34 | 78.55 | 77.25 | +1.08 | +1.40% | 938.54K | Toronto | |||
| 0.15 | 0.15 | 0.15 | 0.00 | 0.00% | 0.00 | CSE | |||
| 89.97 | 90.97 | 89.27 | -1.05 | -1.15% | 4.39M | Toronto | |||
| 778.06 | 779.48 | 760.80 | +14.06 | +1.84% | 51.99K | Toronto | |||
| 62.00 | 62.08 | 60.81 | +1.12 | +1.84% | 2.61M | Toronto | |||
| 15.32 | 15.60 | 15.26 | -0.30 | -1.92% | 118.28K | Toronto | |||
| 0.29 | 0.31 | 0.29 | -0.0200 | -6.45% | 91.94K | TSXV | |||
| 28.92 | 29.12 | 28.73 | -0.12 | -0.41% | 4.31M | Toronto | |||
| 1.63 | 1.655 | 1.62 | -0.0400 | -2.40% | 351.74K | Toronto | |||
| 0.20 | 0.20 | 0.20 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.06 | 0.06 | 0.06 | 0.00 | 0.00% | 0.00 | TSXV |